Hyperstabilized c-met Inhibitors for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The HGF/c-met signaling pathway is difficult to target therapeutically due to a lack of understanding regarding mechanisms of action by which dysregulation causes tumorigenesis, and existing approaches have been impeded by the complexity of targeting aberrant HGF/c-met pathways in cancers.
Innovation Solution
Development of specific inhibitors targeting hyperstabilized c-met proteins, which exhibit decreased down-regulation and increased oncogenic activity, to inhibit their activity and diminish tumorigenesis, using substances such as antibodies, aptamers, and antisense oligonucleotides that bind to mutated c-met epitopes or inhibit expression, thereby reducing tumorigenic signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutic approaches target the HGF/c-met pathway, then tumorigenesis can be inhibited, but the treatment complexity increases due to the difficulty of targeting aberrant pathways specifically
Solution Approach 1:
The patent applies local quality by developing inhibitors that specifically target hyperstabilized c-met proteins with unique structural characteristics (exon 14 deletions) found in tumor cells. The antibodies are engineered to recognize epitopes present only in the mutated c-met isoforms, allowing selective inhibition of tumorigenic signaling while sparing wild-type c-met in normal cells, thus reducing treatment complexity associated with non-specific targeting
Solution Approach 2:
The patent segments the c-met receptor family by focusing on a specific mutated isoform (c-met exon 14 deletion variants) that is overrepresented in tumors. By developing inhibitors that specifically bind to this segmented target population rather than all c-met receptors, the approach simplifies the therapeutic strategy while maintaining high efficacy against tumorigenesis driven by these specific hyperstabilized variants
2Reliability
If broad c-met inhibition is used to treat cancers, then tumorigenesis can be suppressed, but side effects increase due to inhibition of normal c-met function
Solution Approach 1:
The patent employs local quality by engineering antibodies with specificity for epitopes unique to hyperstabilized c-met mutants found in tumors. This allows the treatment to locally target only the pathological c-met variants while leaving wild-type c-met in normal cells unaffected, thereby suppressing tumorigenesis while minimizing side effects from off-target inhibition
Solution Approach 2:
The patent uses specifically designed monoclonal antibodies as intermediaries that selectively bridge the inhibitor function to only the hyperstabilized c-met targets. These antibody intermediaries recognize unique structural features of the mutated c-met isoforms (such as altered juxtamembrane domains from exon 14 deletions) and mediate inhibition exclusively against these tumor-specific variants, preventing broad suppression of normal c-met function
3Object-affected harmful factors
If targeted inhibitors are developed for hyperstabilized c-met, then side effects are reduced, but the manufacturing complexity increases due to need for specific antibody development
Solution Approach 1:
The patent applies preliminary action by first identifying and characterizing the unique epitopes present on hyperstabilized c-met mutants (such as those resulting from exon 14 deletions) before developing the inhibitors. This preliminary characterization of target specificity allows for rational antibody design and selection, streamlining the development process while ensuring the inhibitors will achieve the desired selectivity and reduced side effect profile
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The targeted inhibition of hyperstabilized c-met activity diminishes tumorigenesis and reduces side effects by specifically addressing tumor-specific mutants, offering a therapeutic benefit in treating cancers driven by aberrant HGF/c-met signaling.
Implementation Method 1
using substances such as antibodies, aptamers, and antisense oligonucleotides that bind to mutated c-met epitopes or inhibit expression
Implementation Method 2
antisense oligonucleotides that bind to mutated c-met epitopes or inhibit expression
Data Source
Figure 1
Figure 2A~2B
Figure 2C~2D
AI summary
The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by inhibiting a hyperstabilized c-met protein.